D
Devinder Gill
Researcher at Princess Alexandra Hospital
Publications - 122
Citations - 8943
Devinder Gill is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Chronic lymphocytic leukemia & Rituximab. The author has an hindex of 31, co-authored 120 publications receiving 7835 citations. Previous affiliations of Devinder Gill include University of Queensland & Translational Research Institute.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh,Lorenz Trümper,Anders Österborg,Ruth Pettengell,Marek Trneny,Kevin Imrie,David D.F. Ma,Devinder Gill,Jan Walewski,Pier Luigi Zinzani,Rolf A. Stahel,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Tuula Lehtinen,Armando López-Guillermo,Claudia Corrado,Adriana Scheliga,Noel Milpied,Myriam Mendila,Michelle Rashford,Evelyn Kuhnt,Markus Loeffler +23 more
TL;DR: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Journal ArticleDOI
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
TL;DR: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Journal ArticleDOI
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht,Bertram Glass,Nicolas Mounier,Devinder Gill,David C. Linch,Marek Trneny,André Bosly,Nicolas Ketterer,Ofer Shpilberg,Hans Hagberg,David D.F. Ma,Josette Brière,Craig H. Moskowitz,Norbert Schmitz +13 more
TL;DR: It is found that patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
Journal ArticleDOI
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Michael Pfreundschuh,Evelyn Kuhnt,Lorenz Trümper,Anders Österborg,Marek Trneny,Lois E. Shepherd,Devinder Gill,Jan Walewski,Ruth Pettengell,Ulrich Jaeger,Pier Luigi Zinzani,Ofer Shpilberg,Stein Kvaløy,Peter de Nully Brown,Rolf A. Stahel,Noel Milpied,Armando López-Guillermo,Viola Poeschel,Sandra Grass,Markus Loeffler,Niels Murawski +20 more
TL;DR: Rituximab added to six cycles of CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows a more refined therapeutic approach to these patients than does assessment by IPI alone.
Journal ArticleDOI
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno,Richard Greil,Fatih Demirkan,Alessandra Tedeschi,Bertrand Anz,Loree Larratt,Martin Simkovic,Olga Samoilova,Jan Novák,Dina Ben-Yehuda,Vladimir Strugov,Devinder Gill,John G. Gribben,Emily Hsu,Chih-Jian Lih,Cathy Zhou,Fong Clow,Danelle F. James,Lori Styles,Ian W. Flinn +19 more
TL;DR: The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population and median progression- free survival was significantly longer in the ibrutinib plus obinutuzumab group than in the chlorambucil plus ob inutuzuab group.